Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 11:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–42 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Lidocaine patch 5% Clear all
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Trigger Point Injections Versus Lidocaine Patch for Myofascial Pain in the Emergency Department

NCT05151510
View directory record Official record
Conditions
Myofascial Trigger Point Pain, Myofacial Pain
Interventions
Trigger point injection with 1% lidocaine, Lidocaine patch 5%
Procedure · Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 28, 2026, 11:58 PM EDT
Completed Phase 2 Interventional

Pilot Study of Lidocaine 5% Patch Versus Placebo in Patients With Osteoarthritis Pain of the Knee

NCT00904462
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Lidoderm, Placebo patch
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
24
States / cities
Birmingham, Alabama • Hueytown, Alabama • Tallassee, Alabama + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2010 · Synced Sep 28, 2026, 11:58 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The OBstetric Lidocaine Patch (OBLido) Trial

NCT03810235
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Transdermal Lidocaine Patch, Transdermal Hydrocolloid Placebo Patch
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 59 Years · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Sep 28, 2026, 11:58 PM EDT
Completed Not applicable Interventional

Optimal Performance of RFA of the Nerves Supplying the Posterior Sacroiliac Joint Complex.

NCT02808962
View directory record Official record
Conditions
Osteoarthritis Nos, of Sacroiliac Joint
Interventions
Cooled RFA of sacral lateral branches
Procedure
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2022 · Synced Sep 28, 2026, 11:58 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of Lidocaine in Healthy Adults

NCT03310970
View directory record Official record
Conditions
Healthy
Interventions
Lidocaine 5% patch, Lidocaine hydrochloride, Lidoderm 5% patch
Drug
Lead sponsor
Nicole K Brogden
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 28, 2026, 11:58 PM EDT
Completed Phase 2 Interventional Results available

Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)

NCT00499083
View directory record Official record
Conditions
Breast Cancer
Interventions
therapeutic autologous dendritic cells, aromatase inhibition therapy, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate, gene expression analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, adjuvant therapy, biopsy, conventional surgery, neoadjuvant therapy, radiation therapy
Biological · Drug · Genetic + 3 more
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 120 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Tampa, Florida • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Sep 28, 2026, 11:58 PM EDT
Active, not recruiting Not applicable Interventional

Trident Multi-tined Cannula for Cervical MBRFA Compared to the Conventional Cannula

NCT05424198
View directory record Official record
Conditions
Cervical Pain, Cervical Facet Joint Pain
Interventions
Cervical Medial Branch Radiofrequency Ablation
Procedure
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Farmington, Utah • Salt Lake City, Utah • South Jordan, Utah
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 28, 2026, 11:58 PM EDT
Completed Phase 4 Interventional

A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions

NCT00904202
View directory record Official record
Conditions
Postherpetic Neuralgia, Diabetic Neuropathy, Complex Regional Pain Syndrome, Carpal Tunnel Syndrome, HIV Neuropathy, Idiopathic Sensory Neuropathy, Peripheral Neuropathy
Interventions
Placebo Capsules + Placebo Patch, Placebo capsules + Lidoderm®, Gabapentin + Placebo, Gabapentin + Lidoderm®, Gabapentin 300 mg capsules 1800 mg/day + placebo patch, Gabapentin 1800 mg/day + Lidoderm patch
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
7
States / cities
Birmingham, Alabama • Hueytown, Alabama • Phoenix, Arizona + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced Sep 28, 2026, 11:58 PM EDT
Not yet recruiting Phase 4 Interventional

Modality Choice Before and After Failure for the Treatment of Painful Diabetic Neuropathy

NCT07795593
View directory record Official record
Conditions
Painful Diabetic Neuropathy (PDN), Diabetic Nephropathies
Interventions
Cognitive Behavioral Therapy (CBT), Oral Medication, Topical Medication
Device · Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
23
States / cities
Stanford, California • Jacksonville, Florida • Chicago, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2026 · Synced Sep 28, 2026, 11:58 PM EDT
Completed Phase 4 Interventional

Rapydan Topical Anaesthesia for Arterial Cannulation

NCT01494311
View directory record Official record
Conditions
Arterial Catheterization
Interventions
Lidocaine/tetracaine patch, Placebo Patch, Subcutaneous injection of 0.5 ml Lidocain 1%, Subcutaneous injection of saline
Drug
Lead sponsor
Medical University of Vienna
Other
Eligibility
18 Years to 90 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 17, 2013 · Synced Sep 28, 2026, 11:58 PM EDT
Completed Phase 2 Interventional

A Study Comparing The Efficacy And Safety Of Lidocaine 5% Patch With Placebo In Patients With Chronic Axial Low Back Pain

NCT00904111
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Lidoderm®, Placebo Topical Patch
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Carlsbad, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2013 · Synced Sep 28, 2026, 11:58 PM EDT
Not listed Not applicable Interventional

Comparison of Prescription Lidocaine Patch to Over the Counter Lidocaine Patch and Placebo for Back Pain and Arthritis

NCT02749123
View directory record Official record
Conditions
Back Pain, Arthritis
Interventions
lidocaine 5% patch, lidocaine 3.6%, menthol 1.25%, Placebo
Drug
Lead sponsor
J.A.R. Laboratories
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Barrington, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 21, 2016 · Synced Sep 28, 2026, 11:58 PM EDT
Completed Phase 4 Interventional

Lidoderm® (Lidocaine Patch 5%) in Diabetic and Idiopathic Neuropathy

NCT00903851
View directory record Official record
Conditions
Diabetes
Interventions
Lidoderm
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 90 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
4
States / cities
Birmingham, Alabama • Hueytown, Alabama • Jacksonville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2010 · Synced Sep 28, 2026, 11:58 PM EDT
Terminated Phase 4 Interventional Results available

Conventional vs Bipolar SIJ RFA for Treatment of Sacroiliac Joint Pain

NCT05409443
View directory record Official record
Conditions
Sacroiliac Joint Complex, Low Back Pain
Interventions
Nimbus Sacroiliac Joint Radiofrequency Ablation (N-SIJRFA), Conventional Sacroiliac Joint Radiofrequency Ablation (C-SIJRFA)
Procedure
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Farmington, Utah • Salt Lake City, Utah • South Jordan, Utah
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 28, 2026, 11:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Adhesion Performance Study of Lidocaine Topical System 1.8% Compared to Generic Lidocaine Patch 5% in Healthy, Adult, Human Subjects

NCT04319926
View directory record Official record
Conditions
Healthy
Interventions
lidocaine topical system 1.8%, lidocaine patch 5%
Drug
Lead sponsor
Scilex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Dilworth, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 28, 2026, 11:58 PM EDT
Terminated Phase 3 Interventional

Safety and Efficacy of Lidoderm (Lidocaine Patch 5%) in Treating Moderate to Severe Pain Associated With Carpal Tunnel Syndrome

NCT00266214
View directory record Official record
Conditions
Carpal Tunnel Syndrome
Interventions
lidocaine patch 5%
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2011 · Synced Sep 28, 2026, 11:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Depth and Duration of Anesthesia From Heated Lidocaine/Tetracaine (Synera®) Patches Compared With 5% Lidocaine (Lidoderm®) Patches Applied to Healthy Adult Volunteers

NCT01688518
View directory record Official record
Conditions
Healthy
Interventions
Heated Lidocaine/Tetracaine Patch, 5% Lidocaine Patch
Drug
Lead sponsor
CRI Lifetree
Other
Eligibility
18 Years to 60 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Sep 28, 2026, 11:58 PM EDT
Completed Phase 4 Interventional

Topical Lidocaine Patch in Low Back Pain

NCT00904540
View directory record Official record
Conditions
Acute and Chronic Non-radicular LBP
Interventions
Lidoderm®
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
7
States / cities
Phoenix, Arizona • Mill Valley, California • Weston, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced Sep 28, 2026, 11:58 PM EDT